Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Operating Leases: 2022-2024

Historic Operating Leases for Fulcrum Therapeutics (FULC) over the last 3 years, with Dec 2024 value amounting to $6.4 million.

  • Fulcrum Therapeutics' Operating Leases fell 33.49% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year decrease of 33.49%. This contributed to the annual value of $6.4 million for FY2024, which is 25.33% down from last year.
  • According to the latest figures from FY2024, Fulcrum Therapeutics' Operating Leases is $6.4 million, which was down 25.33% from $8.6 million recorded in FY2023.
  • In the past 5 years, Fulcrum Therapeutics' Operating Leases registered a high of $10.8 million during FY2022, and its lowest value of $6.4 million during FY2024.
  • In the last 3 years, Fulcrum Therapeutics' Operating Leases had a median value of $8.6 million in 2023 and averaged $8.6 million.
  • Data for Fulcrum Therapeutics' Operating Leases shows a maximum YoY dropped of 25.33% (in 2024) over the last 5 years.
  • Over the past 3 years, Fulcrum Therapeutics' Operating Leases (Yearly) stood at $10.8 million in 2022, then fell by 20.26% to $8.6 million in 2023, then decreased by 25.33% to $6.4 million in 2024.